365 related articles for article (PubMed ID: 23568101)
1. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
Faivre E; Hölscher C
J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
[TBL] [Abstract][Full Text] [Related]
2. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
4. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
5. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
Gengler S; McClean PL; McCurtin R; Gault VA; Hölscher C
Neurobiol Aging; 2012 Feb; 33(2):265-76. PubMed ID: 20359773
[TBL] [Abstract][Full Text] [Related]
6. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice.
Faivre E; Hamilton A; Hölscher C
Eur J Pharmacol; 2012 Jan; 674(2-3):294-306. PubMed ID: 22115896
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
McClean PL; Jalewa J; Hölscher C
Behav Brain Res; 2015 Oct; 293():96-106. PubMed ID: 26205827
[TBL] [Abstract][Full Text] [Related]
8. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
9. Impairment of Spike-Timing-Dependent Plasticity at Schaffer Collateral-CA1 Synapses in Adult APP/PS1 Mice Depends on Proximity of Aβ Plaques.
Garad M; Edelmann E; Leßmann V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573114
[TBL] [Abstract][Full Text] [Related]
10. DAla2-GIP-GLU-PAL Protects Against Cognitive Deficits and Pathology in APP/PS1 Mice by Inhibiting Neuroinflammation and Upregulating cAMP/PKA/CREB Signaling Pathways.
Yuan L; Zhang J; Guo JH; Holscher C; Yang JT; Wu MN; Wang ZJ; Cai HY; Han LN; Shi H; Han YF; Qi JS
J Alzheimers Dis; 2021; 80(2):695-713. PubMed ID: 33579843
[TBL] [Abstract][Full Text] [Related]
11. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1δE9-deleted transgenic mice model of ß-amyloidosis.
Volianskis A; Køstner R; Mølgaard M; Hass S; Jensen MS
Neurobiol Aging; 2010 Jul; 31(7):1173-87. PubMed ID: 18790549
[TBL] [Abstract][Full Text] [Related]
12. Colivelin Ameliorates Impairments in Cognitive Behaviors and Synaptic Plasticity in APP/PS1 Transgenic Mice.
Wu M; Shi H; He Y; Yuan L; Qu X; Zhang J; Wang Z; Cai H; Qi J
J Alzheimers Dis; 2017; 59(3):1067-1078. PubMed ID: 28731445
[TBL] [Abstract][Full Text] [Related]
13. Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.
Wang T; Wang CY; Shan ZY; Teng WP; Wang ZY
J Alzheimers Dis; 2012; 29(3):549-59. PubMed ID: 22269164
[TBL] [Abstract][Full Text] [Related]
14. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
[TBL] [Abstract][Full Text] [Related]
15. FK506 reduces amyloid plaque burden and induces MMP-9 in AβPP/PS1 double transgenic mice.
Hong HS; Hwang JY; Son SM; Kim YH; Moon M; Inhee MJ
J Alzheimers Dis; 2010; 22(1):97-105. PubMed ID: 20847451
[TBL] [Abstract][Full Text] [Related]
16. Lesion-induced hippocampal plasticity in transgenic Alzheimer's disease mouse models: influences of age, genotype, and estrogen.
Kadish I; van Groen T
J Alzheimers Dis; 2009; 18(2):429-45. PubMed ID: 19584452
[TBL] [Abstract][Full Text] [Related]
17. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice.
Cheng D; Spiro AS; Jenner AM; Garner B; Karl T
J Alzheimers Dis; 2014; 42(4):1383-96. PubMed ID: 25024347
[TBL] [Abstract][Full Text] [Related]
18. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
[TBL] [Abstract][Full Text] [Related]
19. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
McClean PL; Parthsarathy V; Faivre E; Hölscher C
J Neurosci; 2011 Apr; 31(17):6587-94. PubMed ID: 21525299
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
